Research location
Ostrava
Czech Republic, Czechia
Advertisement
Research activity in Ostrava
Czech Republic, CzechiaCureCurrent currently publishes aggregate city-level research activity for this location: 12 trials and 12 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Ostrava
12 linked trials · page 1 of 1Fetuin A as a Predictor of Deterioration of Renal Function in Hypertonic PatientsNCT05963126 · 2023-07-01 · 1 site observation
RECRUITING
Determination of Drug Levels for Pharmacotherapy of Heart FailureNCT06035978 · 2024-03-01 · 1 site observation
UNKNOWN
Bioelectrical Impedance in Monitoring Hyperhydration and Polyneuromyopathy in Critically Ill PatientsNCT05991778 · 2021-03-01 · 1 site observation
COMPLETED
Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection FractionNCT01920711 · 2014-07-18 · 1 site observation
COMPLETED
Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid ArthritisNCT02092467 · 2014-03-14 · 1 site observation
COMPLETED
Study to Evaluate the Efficacy and Safety of Glycopyrronium or Indacaterol Maleate and Glycopyrronium Bromide Fixed-dose Combination Regarding Symptoms and Health Status in Patients With Moderate COPD Switching From Treatment With Any Standard COPD RegimenNCT01985334 · 2014-02-14 · 1 site observation
COMPLETED
QVA vs. Salmeterol/Fluticasone, 52-week Exacerbation Study, FLAME (EFfect of Indacaterol Glycopyronium Vs Fluticasone Salmeterol on COPD Exacerbations)NCT01782326 · 2013-07-01 · 1 site observation
COMPLETED
PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME)NCT01445899 · 2012-02-01 · 1 site observation
COMPLETED
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1)NCT01350804 · 2011-09-01 · 1 site observation
COMPLETED
Efficacy, Safety and Tolerability of AIN457 in Patients With Rheumatoid Arthritis (RA) Taking Methotrexate (MTX)NCT00928512 · 2009-07-01 · 1 site observation
COMPLETED
Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart FailureNCT00853658 · 2009-03-01 · 1 site observation
COMPLETED
Exacerbation StudyNCT00845728 · 2009-03-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.